NEW YORK – Bristol Myers Squibb said on Wednesday that the addition of nivolumab (Opdivo) to standard-of-care chemoradiation has failed to extend overall survival in patients with MGMT-methylated brain cancer.
NEW YORK – Bristol Myers Squibb said on Wednesday that the addition of nivolumab (Opdivo) to standard-of-care chemoradiation has failed to extend overall survival in patients with MGMT-methylated brain cancer.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.